US FDA approves Ipsen's SohonosTM (palovarotene) capsules,

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...

Related Keywords

France ,Paris ,France General ,Canada ,Shanghai ,China ,United Arab Emirates ,Saclay ,San Francisco ,California ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Edward Hsiao ,Amy Wolf ,Howard Mayer ,Rachel Reiff ,Ipsen Euronext ,Anna Gibbins ,Nicolas Bogler ,Al Mukaddam ,Michelle Davis ,Ioana Piscociu ,Val Health ,European Commission ,University Of California ,Global Head Of Franchise Communications ,International Fibrodysplasia Ossificans Progressiva ,Drug Administration ,Association Global Registry ,Division Of Endocrinology ,Mineral Research ,Us Head Of Franchise Communications ,Head Of Research ,Executive Director ,Ipsen Cares ,Orphan Drug ,Breakthrough Therapy Designations ,Priority Review ,New Drug Application ,United Arab ,Rare Pediatric Disease Priority Review Voucher ,Fetal Toxicity ,Epiphyseal Closure ,Growing Pediatric Patients ,Adverse Reactions ,Bone Disorders ,Reproductive Potential ,Hepatic Impairment ,Prescribing Information ,Rare Disease ,Sponsored Level ,American Depositary Receipt ,Corporate Brand Strategy ,Franchise Communications ,French Autorit ,Des March ,Universal Registration Document ,Association Global ,Natural History ,Fibrodysplasia Ossificans Progressiva ,Endocrinol Rev ,Early Mortality ,Cardiorespiratory Failure ,Fibrodysplasia Ossificans ,Multiple Additions ,Prescription Drug List ,Paris Stock Exchange Ipn ,Ipsen Pharma ,